GlassScriptPhysician profile
Oney Zuniga
NPI 1689658627
$4,064.15
in general payments reported to CMS, 2019-2025
29 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,126 · 2020: $991 · 2021: $895 · 2022: $479 · 2023: $239 · 2024: $110 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566 · Education: $7.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.78 |
| Education | $7.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,107.88 | 2019-2022 | |
| Vifor Pharma, INC. | $517.25 | 2019-2023 | Veltassa, Korsuva |
| Acadia Pharmaceuticals INC | $493.24 | 2019-2025 | Nuplazid |
| Sanofi-Aventis U.S. LLC | $293.56 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $190.32 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $157.30 | 2020-2025 | Farxiga |
| Sumitomo Pharma America, INC. | $156.82 | 2023-2024 | Aptiom |
| Avanir Pharmaceuticals, INC. | $145.40 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $117.62 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $114.85 | 2021 | |
| Novo Nordisk INC | $98.04 | 2020-2025 | Ozempic |
| Glaxosmithkline, LLC. | $92.95 | 2022-2025 | Benlysta, Shingrix, Arexvy |
| Lilly USA, LLC | $80.65 | 2020-2022 | |
| Pfizer INC. | $76.88 | 2020-2022 | |
| Horizon Therapeutics Plc | $73.40 | 2019-2023 | Krystexxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $44.33 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $44.29 | 2019-2020 | |
| Kerecis Limited | $35.76 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Melinta Therapeutics, LLC | $30.76 | 2019 | |
| Nevro Corp. | $27.36 | 2022 | |
| Eisai INC. | $26.13 | 2022 | |
| Travere Therapeutics, INC. | $24.04 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $22.94 | 2022 | |
| Mallinckrodt Enterprises LLC | $21.11 | 2019 | |
| Tactile Systems Technology INC | $16.72 | 2019 | |
| Opko Pharmaceuticals, LLC | $16.14 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.60 | 2025 | Nuzyra |
| Amgen INC. | $12.39 | 2022 | |
| Normatec Industries, LP | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oney Zuniga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.